ArticleAsian Pacific journal of cancer prevention : APJCP2025
The Expression of Semaphorin 3G (SEMA3G) Protein in Breast Cancer Tissue by the Immunohistochemistry Method.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveBreast cancer is a major health issue for women worldwide, with high incidence rates and as one of the primary causes of mortality among women. However, molecular studies related to the development and spread of breast cancer are still not well understood. According to research reports, the Semaphorin 3G (SEMA3G) gene significantly contributes to the growth and dissemination of cancer cells. The aim of this study was to compare the expression of the SEMA3G protein found in healthy breast tissue versus breast cancer patient tissue and to investigate the correlation between SEMA3G protein expression and the spread of breast cancer cells to axillary lymph nodes, as well as other clinical data, using immunohistochemistry.
resultsFrom the study of 88 breast tissue samples, it was found that SEMA3G levels, with an immunohistochemistry (IHC) index > 4, were significantly higher in breast cancer tissue compared to normal breast tissue (P-value < 0.0001, OR (95% CI) = 8.565 to +infinity). Moreover, SEMA3G protein expression (IHC index > 6) was detected at elevated levels in breast cancer tissue that had spread to axillary lymph nodes compared with breast cancer tissue without lymph node metastasis (P-value = 0.038, OR (95% CI) = 4.41 (1.19-13.81)). Additionally, the study found a positive correlation between high SEMA3G protein expression and HER2-positive breast cancer.
conclusionsHigher SEMA3G expression was significantly associated with breast cancer presence, axillary lymph node metastasis, and HER2 positivity, indicating that SEMA3G may play a role in tumor aggressiveness and could serve as a potential marker for disease progression, with potential implications for clinical decision-making in treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.